Arcturus Therapeutics (ARCT) Tops Q3 EPS by $1.01

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.61), $1.01 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $45.1 million versus the consensus estimate of $15.61 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Syra Health names Dr. Cori McMahon as fractional chief medical officer
• Redwood Trust reports record Aspire quarter, launches AI pricing tools